Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AKUMS.NS
Strong BuyPremium GrowerAkums Drugs and Pharmaceuticals Limited · Healthcare · India · $1.2B · Avg Vol: $3M/d
95
StockRankGet insider-trade alerts
Q
71
V
45
M
85
P/E (TTM)
38.8x
ROE
7.7%
D/E
0.1x
Dividend %
0.4%
COMPANY DESCRIPTION
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.7B | 40.2B | 40.7B | 42.5B | 7.0% | 45.0B | 49.0B | 56.4B | 15.2% |
| EPS (INR) | 6.03 | -0.28 | 22.60 | 16.67 | 40.4% | 19.08 | 25.87 | — | 55.2% |
| Shares | 153.1M | 153.1M | 153.1M | 153.1M | -0.0% | 153.1M | — | — | — |
| Debt | 6.2B | 5.7B | 882.1M | 1.9B | -32.3% | 1.9B | — | — | — |
| Equity | 7.2B | 7.1B | 30.5B | 33.1B | 66.5% | — | — | — | — |
| Op CF | 1.8B | 5.0B | 4.7B | 11.8B | 88.4% | 11.8B | — | — | — |
| Inv CF | -3.0B | -3.3B | -5.5B | -9.3B | — | — | — | — | — |
| Fin CF | 1.2B | -1.1B | 727.9M | 338.8M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+12.2%
SMA 50SMA 200
Close
$7.79
RSI (14)
46.3
52W High
$8.38
From 52W High
0.9%
SCORE BREAKDOWN
Quality
71
ROIC
11.9%76.1
ROE
7.7%63.5
GP/Assets
34.0%69.7
Op. Margin
11.5%66.5
FCF/Assets
17.5%95.1
Piotroski
668.8
Int. Cover
5.6x53.2
D/E Ratio
0.06x69.5
Current Ratio
3.25x58.4
Value
45
P/E (TTM)
38.8x29.2
EV/EBITDA
17.7x39.9
P/FCF
11.9x79.9
P/B
3.4x41.0
P/S
2.5x62.1
Div Yield
0.4%12.3
Momentum
85
52W High %
93%89.9
RS 6M
53%91.6
SMA 50/200
1.30x93.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+79%67.8
Q Growth
58%76.4
FUNDAMENTALS
Market Cap
$1.2B
P/E (Forward)
21.7x
Gross Margin
41.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AKUMS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AKUMS.NS | Akums Drugs and Pharmaceuticals Limited(you) | $1.2B | 95 | Strong Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 93 | Strong Buy |
| PGHL.NS | Procter & Gamble Health Limited | $981M | 92 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 91 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $696M | 89 | Strong Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $653M | 89 | Strong Buy |
| MOREPENLAB.NS | Morepen Laboratories Limited | $677M | 85 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.8x · Gross margin 59.4%